Mirum Pharmaceuticals, Inc. (MIRM) Misses Q2 EPS by 32c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts MIRM Hot Sheet
Join SI Premium – FREE
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q2 EPS of ($1.06), $0.32 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $176 million versus the consensus estimate of $166.03 million.
FY 2026 Outlook:-
Revenue between $680 million to $700 million vs consensus $678 million.
For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kotak Upgrades Indusind Bank Ltd (IIB:IN) to Reduce (3)
- Dr. Reddy\'s Laboratories (DRRD:IN) (RDY) PT Raised to INR1,220 at Kotak
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
